Search for: "Daubert v. Merrell Dow Pharmaceuticals, Inc."
Results 241 - 260
of 284
Sorted by Relevance
|
Sort by Date
10 Jun 2012, 1:09 pm
Merrell Dow Pharms., Inc., 874 F.2d 307, 311 (5th Cir. 1989) (noting that “[o]ne difficulty with epidemiologic studies is that often several factors can cause the same disease. [read post]
31 Oct 2018, 10:04 am
In some instances, especially in studies pharmaceutical adverse outcomes, there is the danger that the hypothesized outcome is also a feature of the underlying disease being treated. [read post]
6 May 2010, 4:12 pm
Metabolife International, Inc., 401 F.3d 1233, 1247 (11th Cir. 2005); Goebel v. [read post]
12 Dec 2017, 6:00 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993) also increased the admissibility of expert witness testimony, as the decision adopted a more flexible reliability standard for admissibility then the previous long-held standard set forth in Frye v. [read post]
6 Nov 2018, 5:00 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), which enumerated a non-exhaustive list of factors for the courts to consider when determining whether to admit expert testimony. [read post]
14 May 2012, 8:24 am
Perrier Group of America Inc., 986 F. [read post]
18 Jan 2015, 10:17 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), the U.S. [read post]
31 Jan 2014, 7:11 am
Merrell Dow Pharmaceuticals, Inc. [read post]
1 Jun 2014, 7:45 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), and Wilt v. [read post]
5 Feb 2018, 11:59 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). [read post]
12 Nov 2014, 8:01 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 599 (1993) (Rehnquist, C.J., concurring in part and dissenting in part) (‘‘the various briefs filed in this case … deal with definitions of scientific knowledge, scientific method, scientific validity, and peer review—in short, matters far afield from the expertise of judges’’); Marconi Wireless Telegraph Co. of America v. [read post]
10 Apr 2018, 6:00 am
Once the computer simulation is broken into these two parts, the analysis can be evaluated like any other analysis using Rule 702,[2] Daubert,[3] or the applicable law in the jurisdiction. [read post]
22 Dec 2009, 8:57 pm
Digital Sys., Inc. v. [read post]
6 Feb 2014, 6:31 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993), and need not find facts when evidence is disputed in these cases.[10] In 2005, the Federal Circuit sat en banc in Phillips. [read post]
19 Oct 2015, 11:11 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993), and State v. [read post]
8 Dec 2008, 5:45 am
Merrell Dow Pharmaceuticals (1993) 509 U.S. 579. [read post]
19 Jun 2018, 6:00 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), guides federal court analysis in determining admissibility of expert testimony. [read post]
31 Jan 2014, 8:25 am
Merrell Dow Pharmaceuticals. [read post]
21 Oct 2008, 8:15 pm
Merrell Dow Pharmaceuticals seems to break down as well. [read post]
18 Sep 2019, 10:02 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S. [read post]
